Lymphoma treatment guidelines
| Disease | Date | Guideline |
| DLBCL | Sept2021 | DLBCL guideline Dutch only) |
| MCL | 11OCT2017 | MCL guideline (Dutch only) |
| - | Please also find associated trials at the LLPC section | |
| FL | 04FEB2020 | Folliculair Lymphoma guideline (Dutch only) |
| HL | 13NOV2019 | Hodgkin Lymphoma guideline (Dutch only) |
| MW | Jul 2022 | Morbus Waldenstrom guideline (Dutch only) |
| MZL | Sept2021 | Marginale Zone Lymfoom guideline (Dutch only) |
| BL | 11JAN2023 | Burkitt Lymphoma guideline (Dutch only) |
DLBCL treatment with Yescarta
As of May 1, 2020, Yescarta (axicabtagene ciloleucel) is included in the basic package for patients with relapsed / refractory DLBCL (including transformed LF and PMBCL) after at least 2 previous lines of systemic therapy. To make this treatment possible for all eligible patients, there is a central registration procedure and the indication is discussed in national consultation. More information about the application procedure and inclusion / exclusion criteria for treatment can be found in the following documents:
CD19 CAR T-cel update (06MAY2020)
Landelijk verwijsformulier CD19 CAR-T cel behandeling buiten studieverband (13JUN2022)
DLBCL treatment with Kymriah
Kymriah (Tisagenlecleucel) is available since 01/06/2022 for the following 2 indications:
1. Pediatric and young adult patients up to the age of 25 years with refractory B cell acute lymphoblastic leukemia (ALL), or with relapse after transplantation or with second or later recurrence of B cell ALL (hereinafter referred to as r/r B cell ALL )
2. Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after 2 or more lines of systemic therapy.
Landelijk verwijsformulier CD19 CAR-T cel behandeling buiten studieverband (13JUN2022)